Deszcz Iwona
Department of Immunopathology and Molecular Biology, Wroclaw Medical University, Borowska 211, 50-556, Wroclaw, Poland.
Stem Cells Int. 2023 Nov 2;2023:2729377. doi: 10.1155/2023/2729377. eCollection 2023.
The World Health Organization reports that cardiovascular diseases (CVDs) represent 32% of all global deaths. The ineffectiveness of conventional therapies in CVDs encourages the development of novel, minimally invasive therapeutic strategies for the healing and regeneration of damaged tissue. The self-renewal capacity, multilineage differentiation, lack of immunogenicity, and immunosuppressive properties of mesenchymal stem cells (MSCs) make them a promising option for CVDs. However, growing evidence suggests that myocardial regeneration occurs through paracrine factors and extracellular vesicle (EV) secretion, rather than through differentiation into cardiomyocytes. Research shows that stem cells secrete or surface-shed into their culture media various cytokines, chemokines, growth factors, anti-inflammatory factors, and EVs, which constitute an MSC-conditioned medium (MSC-CM) or the secretome. The use of MSC-CM enhances cardiac repair through resident heart cell differentiation, proliferation, scar mass reduction, a decrease in infarct wall thickness, and cardiac function improvement comparable to MSCs without their side effects. This review highlights the limitations and benefits of therapies based on stem cells and their secretome as an innovative treatment of CVDs.
世界卫生组织报告称,心血管疾病(CVD)占全球总死亡人数的32%。传统疗法在心血管疾病治疗中的无效性促使人们开发新型微创治疗策略,以促进受损组织的愈合和再生。间充质干细胞(MSC)的自我更新能力、多向分化能力、缺乏免疫原性以及免疫抑制特性使其成为治疗心血管疾病的一个有前景的选择。然而,越来越多的证据表明,心肌再生是通过旁分泌因子和细胞外囊泡(EV)分泌实现的,而非通过分化为心肌细胞。研究表明,干细胞会分泌或向其培养基中释放各种细胞因子、趋化因子、生长因子、抗炎因子和细胞外囊泡,这些物质构成了MSC条件培养基(MSC-CM)或分泌组。使用MSC-CM可通过驻留心脏细胞的分化、增殖、减少瘢痕组织、降低梗死壁厚度以及改善心脏功能来增强心脏修复,且效果与间充质干细胞相当,但无其副作用。本综述重点介绍了基于干细胞及其分泌组的疗法作为心血管疾病创新治疗方法的局限性和益处。